Ashwagandha for weight loss: what the trials measured
Reviewed 18 sourcesPublished by PepVault
Does ashwagandha help you lose weight? Every human trial that weighed people, in one table, beside the Wegovy and Zepbound trials, and what the outlier shows.

- Last reviewed
- Sources
- 18
- Questions
- 8
- Compounds
- 3
The short answer
Barely, in most trials. In stressed adults with overweight, ashwagandha took off 1.2 kg more than placebo in 8 weeks, and a 2026 meta-analysis of four trials found no effect on weight or body fat. One 2025 trial is the outlier: 8.5 kg against 2.4 kg over 24 weeks, not yet repeated. Wegovy's main trial took off 14.9% of body weight, Zepbound's 20.9%.
Evidence: Eleven small randomized placebo-controlled trials (38 to 111 people, 40 days to 6 months), most using maker-supplied extracts, and a 2026 meta-analysis of four trials; phase 3 trials for Wegovy and Zepbound.

Does ashwagandha help you lose weight?
A little, in the trials that looked, and mostly in people under stress. Ashwagandha is a root extract from the Ayurvedic tradition, sold for stress and sleep (its full profile: pepvault.app/peptides/ashwagandha). Its weight record is small: every placebo-controlled trial (pepvault.app/glossary/placebo) that weighed people or measured their body fat was small and short, and only three were designed around weight in people with overweight123.
The best-known one, in 50 stressed adults with overweight, found 2.32 kg lost on ashwagandha against 1.13 kg on placebo over 8 weeks: about 3% of body weight against 1.5%1. A 2026 meta-analysis (pepvault.app/glossary/meta-analysis), which pooled four trials and 191 people, found no effect on body weight and none on body fat percentage12; three of its four trials were strength-training trials in young adults. Its search ended in February 2026 and did not include the largest result, a 24-week trial with a loss more than three times bigger than the 8-week one2.
PepVault's weight log draws your trend week by week beside the capsules you log, so after 8 or 12 weeks you can see your own line against the trials' numbers. Track your weight in PepVault

What did each ashwagandha trial find for weight and body fat?
The randomized trials of ashwagandha alone against placebo that reported weight, BMI (pepvault.app/glossary/bmi), body fat or waist as a result:
| Trial | Who | Amount studied, length | Result vs placebo |
|---|---|---|---|
| Choudhary 20171 | 50 stressed adults, BMI 25 to 39.9 | 300 mg twice a day, 8 weeks | Weight −2.32 kg vs −1.13 kg; BMI −0.79 vs −0.38 |
| Pakhale 20252 | 91 adults, BMI 25 to 39.9 | 300 mg twice a day, 24 weeks | Weight −8.46 kg vs −2.41 kg; BMI −3.31 vs −0.93 |
| Ballesteros-Torres 20253 | 38 adults with overweight and high blood fats, on a meal plan | 500 mg once a day, 40 days | Weight −0.42 kg vs +1.14 kg, not significant; waist smaller in women only |
| Smith 20238 | 111 adults aged 40 to 75 with overweight, stress and fatigue | 200 mg twice a day, 12 weeks | No difference in BMI or waist |
| Vaidya 20269 | 40 healthy adults aged 50 to 70, mostly men | 200 mg twice a day, 6 months | Weight no different; waist −0.2 cm vs +1.2 cm |
| Chengappa 201810 | 66 adults with schizophrenia on antipsychotics | 1,000 mg a day, 12 weeks | No difference in weight |
| Verma 202111 | 80 healthy adults | 300 mg twice a day, 8 weeks | No significant change in weight or BMI |
| Wankhede 20154 | 50 young men starting weight training | 300 mg twice a day, 8 weeks | Body fat 21.6% to 18.1% (−3.5 points) vs −1.5 points |
| Ziegenfuss 20185 | 38 men lifting 4 days a week | 500 mg once a day (root and leaf), 12 weeks | Fat and lean mass no different on a DEXA scan; belly-to-hip fat ratio held steady vs a rise on placebo |
| Obhrai 20266 | 63 postmenopausal women aged 45 to 65 | 600 mg a day, 12 weeks | Body fat −0.6 points vs +0.03 on a DEXA scan |
| Charmas 20257 | 38 young men doing interval training | 600 mg a day, 8 weeks | No effect on body composition |
The amounts are what each trial gave, so the table can be read, not a dose for you. The extracts differ (root only, root and leaf, different withanolide content), and three of the trials were funded by the extract's maker589; in three more the maker supplied the extract124. A 2026 review of body-composition trials lists three further trials, in healthy volunteers, people lifting weights and poor sleepers, that logged weight or BMI and found no change against placebo13.
Put together, fewer than 700 people took part in the eleven in the table, against 1,961 in Wegovy's STEP 1 trial alone14. The longest lasted 6 months, and none followed anyone after they stopped.
Why did one trial lose 8.5 kg on ashwagandha?
Nobody knows yet, and it is the number the newest weight-loss articles quote. In the 2025 Mumbai trial, 100 adults with an average BMI of about 31 took 300 mg of the KSM-66 root extract or a starch capsule twice a day, after breakfast and after dinner, for 24 weeks2. The 45 on ashwagandha who finished lost 8.46 kg, 10.7% of their starting weight; the 46 on placebo lost 2.41 kg, 3.0%2.
The gap opened steadily: 1.1 kg at week 4, 3.4 kg at week 12 and 6.1 kg at week 242. Food cravings, one of its secondary measures, fell further on ashwagandha too2.
Three facts set its weight. It ran at one clinic, its weight result counts only the people who finished, and the authors write that diet, sleep and activity were neither monitored nor controlled; people were simply told to keep their usual habits2. The extract's maker supplied the capsules2. And shorter trials at the same daily amount found much less: 1.2 kg more than placebo at 8 weeks in stressed adults1, and no change in healthy volunteers11. One trial of this size is a signal worth repeating, not a settled effect.
Does ashwagandha burn belly fat?
The fat scans say no, or very little. The best tool for this, a DEXA scan (a low-dose X-ray that splits the body into fat, lean tissue and bone), found no change in total fat or lean mass (pepvault.app/glossary/lean-mass) in men lifting weights for 12 weeks; the ratio of belly fat to hip fat held steady on ashwagandha and rose on placebo5. In postmenopausal women, DEXA body fat fell 0.6 points more than on placebo over 12 weeks6.
The biggest drop, 3.5 points of body fat in young men starting weight training against 1.5 points on placebo, came from bioelectrical impedance, the electrode method many bathroom scales use, which moves with how hydrated you are4. A later interval-training trial at the same daily amount found no change at all7. Waist results split: one trial saw a 1.5 cm smaller waist in women only3, one saw 0.2 cm off against 1.2 cm gained on placebo, which its authors call no clinical change9, and a third saw no change8.
The belly-fat claim usually rides on cortisol, the stress hormone. Ashwagandha does lower measured cortisol in trials, and our guide on cortisol belly (pepvault.app/guides/cortisol-belly) sets out how far that goes: none of the cortisol trials measured belly fat.
How does ashwagandha compare with Wegovy and Zepbound?
On the trials' own numbers, ashwagandha's best result reaches about 60% of Wegovy's gap over placebo and about 40% of Zepbound's, with a fraction of the people and the time. These are different trials, people and years, not a head-to-head test:
| Trial | People, length | Weight change, vs placebo | Gap over placebo |
|---|---|---|---|
| Ashwagandha, Choudhary 20171 | 50, 8 weeks | −3.0% vs −1.5% | 1.6 points |
| Ashwagandha, Pakhale 20252 | 91, 24 weeks | −10.7% vs −3.0% | 7.7 points |
| Ashwagandha, Ballesteros-Torres 20253 | 38, 40 days | −0.5% vs +1.3% | Not significant |
| Wegovy 2.4 mg, STEP 114 | 1,961, 68 weeks | −14.9% vs −2.4% | 12.4 points |
| Zepbound 15 mg, SURMOUNT-115 | 2,539, 72 weeks | −20.9% vs −3.1% | 17.8 points |
The ashwagandha percentages are our arithmetic from each paper's kilograms and starting weights; the Wegovy and Zepbound figures are the papers' own.
In STEP 1, 86.4% of people on semaglutide lost 5% or more of their weight14; on tirzepatide 15 mg the figure was 91%15. STEP 1 added a lifestyle program in both arms14, and the two drug trials were about 20 to 28 times larger than the biggest ashwagandha weight trial. Wegovy is semaglutide (pepvault.app/peptides/semaglutide) and Zepbound is tirzepatide (pepvault.app/peptides/tirzepatide); the two labels sit side by side at pepvault.app/drugs/compare/wegovy-vs-zepbound. For other supplements set against the same drugs, see the guide on natural GLP-1 alternatives (pepvault.app/guides/natural-glp-1-alternatives).
How could ashwagandha affect weight at all?
Two routes have evidence, and they differ in strength. The human one is appetite: in both weight trials, scores for food cravings fell more on ashwagandha than on placebo12. Less snacking under stress is a plausible way to a kilogram or two.
The striking one is from mice. Withaferin A, a compound in the plant, made obese mice more sensitive to leptin, the hormone that tells the brain how much fat the body has stored, and they lost 20% to 25% of their body weight16. That was the pure compound injected into the belly cavity of mice, not a capsule in people16, and the extracts in the human trials are standardized to total withanolides, not to withaferin A.
Does ashwagandha make you gain weight?
Not in the trials. Healthy adults on 600 mg a day for 8 weeks had no significant change in weight or BMI11, adults on antipsychotics showed no difference from placebo over 12 weeks10, and none of the eleven trials found people gaining more on ashwagandha than on placebo.
Commonly reported: calmer evenings and less stress snacking after a few weeks, little change on the scale, and some people who say they feel hungrier or put on a little weight, which the trials have not shown.
Who should check before taking ashwagandha for weight?
NCCIH, the US government's centre for complementary health, says ashwagandha may be safe in the short term, up to 3 months; that it should be avoided during pregnancy and not used while breastfeeding; and that it is not recommended before surgery or for people with autoimmune or thyroid disorders17. It may interact with medicines for diabetes and high blood pressure, sedatives and thyroid hormone17. The diabetes point matters most beside a weight-loss plan: someone on a GLP-1 or another glucose-lowering drug brings it to their prescriber.
In the 24-week trial, mild nausea, stomach pain and drowsiness came at rates close to placebo, 7 people against 62. Liver injury is rare: in five documented cases, jaundice began 2 to 12 weeks after starting, none had liver failure, and liver tests returned to normal within 1 to 5 months in the four who were followed18.
PepVault reminds you at the time you set for each compound, so a twice-daily capsule lands after breakfast and after dinner, the schedule the 24-week trial used. Set reminders in PepVault
When to get help Yellowing skin or eyes, dark urine or itching that will not settle are reasons to stop it and contact your clinician18.
Sources
- Choudhary D, Bhattacharyya S, Joshi K. Body weight management in adults under chronic stress through treatment with ashwagandha root extract: a double-blind, randomized, placebo-controlled trial. J Evid Based Complementary Altern Med. 2017. PubMed 27055824
- Pakhale K et al. Efficacy and safety of Ashwagandha (Withania somnifera) root extract on stress and weight management in adults: a prospective, randomized, double-blind, placebo-controlled study. J Med Life. 2025. PubMed 41635453
- Ballesteros-Torres JM et al. Impact of ashwagandha (Withania somnifera L.) supplementation on serum lipid concentrations and anthropometric parameters in adults with overweight and obesity: a double-blind, placebo-controlled pilot study. Nutr Metab (Lond). 2025. PubMed 41204297
- Wankhede S et al. Examining the effect of Withania somnifera supplementation on muscle strength and recovery: a randomized controlled trial. J Int Soc Sports Nutr. 2015. PubMed 26609282
- Ziegenfuss TN et al. Effects of an aqueous extract of Withania somnifera on strength training adaptations and recovery: the STAR trial. Nutrients. 2018. PubMed 30463324
- Obhrai S, Shenoy S, Arora M. Effects of Withania somnifera root extract on sleep quality, body composition, and menopausal symptoms in postmenopausal women: a randomized, double-blind, placebo-controlled trial. Menopause. 2026. PubMed 42742071
- Charmas M et al. Ashwagandha does not enhance the effect of high-intensity interval training on selected energy metabolism parameters in young healthy men. Nutrients. 2025. PubMed 41156498
- Smith SJ, Lopresti AL, Fairchild TJ. Exploring the efficacy and safety of a novel standardized ashwagandha (Withania somnifera) root extract (Witholytin) in adults experiencing high stress and fatigue in a randomized, double-blind, placebo-controlled trial. J Psychopharmacol. 2023. PubMed 37740662
- Vaidya N et al. Safety and tolerability of Withania somnifera root extract in healthy male participants: a pilot randomized, double-blind, placebo-controlled clinical trial. Food Sci Nutr. 2026. PubMed 41458530
- Chengappa KNR et al. Adjunctive use of a standardized extract of Withania somnifera (ashwagandha) to treat symptom exacerbation in schizophrenia: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2018. PubMed 29995356
- Verma N et al. Safety of ashwagandha root extract: a randomized, placebo-controlled, study in healthy volunteers. Complement Ther Med. 2021. PubMed 33338583
- Zhu X et al. Effects of Withania somnifera (L.) Dunal (Ashwagandha) on cognitive and physical function in adults: a systematic review and meta-analysis. Front Pharmacol. 2026. PubMed 42199854
- Castropa GL et al. Effects of Ashwagandha (Withania somnifera) on body composition: a narrative review. Sports (Basel). 2026. PubMed 42931579
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021. PubMed 33567185
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022. PubMed 35658024
- Lee J et al. Withaferin A is a leptin sensitizer with strong antidiabetic properties in mice. Nat Med. 2016. PubMed 27479085
- National Center for Complementary and Integrative Health. Ashwagandha. Last updated March 2023. nccih.nih.gov
- Björnsson HK et al. Ashwagandha-induced liver injury: a case series from Iceland and the US Drug-Induced Liver Injury Network. Liver Int. 2020. PubMed 31991029
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.